de Torre-Minguela Carlos, Mesa Del Castillo Pablo, Pelegrín Pablo
Unidad de Inflamación Molecular, Instituto Murciano de Investigación Biosanitaria-Virgen de la Arrixaca (IMIB-Arrixaca), CIBERehd, Hospital Clínico Universitario Virgen de la Arrixaca , Murcia , Spain.
Unidad de Inflamación Molecular, Instituto Murciano de Investigación Biosanitaria-Virgen de la Arrixaca (IMIB-Arrixaca), CIBERehd, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain; Unidad de Reumatología Pediátrica, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
Front Immunol. 2017 Jan 27;8:43. doi: 10.3389/fimmu.2017.00043. eCollection 2017.
Inflammasomes are multiprotein complexes that critically control different aspects of innate and adaptive immunity. Among them we could highlight the release of pro-inflammatory cytokines that induce and maintain the inflammatory response. Usually, inflammasomes result from oligomerization of a nucleotide-binding domain-like receptor (NLR) after sensing different pathogenic or endogenous sterile dangerous signals; however, other proteins such as absent in melanoma 2, retinoic acid-inducible gene I, or pyrin could also form inflammasome platforms. Inflammasome oligomerization leads to caspase-1 activation and the processing and release of the pro-inflammatory cytokines, such as interleukin (IL)-1β and IL-18. Mutations in different inflammasomes are causative for multiple periodic hereditary syndromes or autoinflammatory diseases, characterized by acute systemic inflammatory flares not associated with infections, tumors, or autoimmunity. This review focuses on germline mutations that have been described in cryopyrin-associated periodic syndrome (CAPS) for or in familial Mediterranean fever (FMF) and pyrin-associated autoinflammation with neutrophilic dermatosis (PAAND) for . Besides the implication of inflammasomes in autoinflammatory syndromes, these molecular platforms are involved in the pathophysiology of different illnesses, including chronic inflammatory diseases, degenerative processes, fibrosis, or metabolic diseases. Therefore, drug development targeting inflammasome activation is a promising field in expansion.
炎性小体是多蛋白复合物,对固有免疫和适应性免疫的不同方面起着关键调控作用。其中,我们可以重点关注促炎细胞因子的释放,这些因子可诱导并维持炎症反应。通常情况下,炎性小体是在感知到不同的病原体或内源性无菌危险信号后,由核苷酸结合结构域样受体(NLR)寡聚化形成;然而,其他蛋白质,如黑色素瘤缺乏因子2、视黄酸诱导基因I或pyrin,也可形成炎性小体平台。炎性小体寡聚化会导致半胱天冬酶-1激活,以及促炎细胞因子如白细胞介素(IL)-1β和IL-18的加工和释放。不同炎性小体的突变是多种周期性遗传性综合征或自身炎症性疾病的病因,其特征为急性全身性炎症发作,与感染、肿瘤或自身免疫无关。本综述重点关注在冷吡啉相关周期性综合征(CAPS)中或家族性地中海热(FMF)以及伴有嗜中性皮肤病的pyrin相关自身炎症(PAAND)中所描述的种系突变。除了炎性小体在自身炎症性综合征中的作用外,这些分子平台还参与了包括慢性炎症性疾病、退行性病变、纤维化或代谢性疾病在内的不同疾病的病理生理学过程。因此,针对炎性小体激活的药物研发是一个正在不断拓展的有前景的领域。